Purinergic P2 Receptor Antagonists
"Purinergic P2 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and block the stimulation of PURINERGIC P2 RECEPTORS.
| Descriptor ID |
D058919
|
| MeSH Number(s) |
D27.505.519.625.725.400.200 D27.505.696.577.725.400.200
|
| Concept/Terms |
Purinergic P2 Receptor Antagonists- Purinergic P2 Receptor Antagonists
- Purinergic P2 Receptor Blockers
- P2 Purinoceptor Blockers
- Blockers, P2 Purinoceptor
- Purinoceptor Blockers, P2
- P2 Purinoceptor Antagonists
- Antagonists, P2 Purinoceptor
- Purinoceptor Antagonists, P2
|
Below are MeSH descriptors whose meaning is more general than "Purinergic P2 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Purinergic P2 Receptor Antagonists".
This graph shows the total number of publications written about "Purinergic P2 Receptor Antagonists" by people in this website by year, and whether "Purinergic P2 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Purinergic P2 Receptor Antagonists" by people in Profiles.
-
Pharmacological characterization of the P2 receptors profile in the podocytes of the freshly isolated rat glomeruli. Am J Physiol Cell Physiol. 2013 Nov 15; 305(10):C1050-9.
-
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011 Dec; 32(23):2933-44.
-
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14; 122(11):1056-67.
-
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J. 2010 Jul; 160(1):65-72.
-
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23; 375(9711):283-93.
-
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J. 2009 Dec; 158(6):998-1004.e1.
-
Identification and functional characterization of the intermediate-conductance Ca(2+)-activated K(+) channel (IK-1) in biliary epithelium. Am J Physiol Gastrointest Liver Physiol. 2009 Nov; 297(5):G1009-18.
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10; 361(11):1045-57.
-
Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. JAMA. 2008 Apr 16; 299(15):1777-87.
-
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007 Nov 06; 50(19):1844-51.